ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸

SOLV // Solventum Corporation

DES <GO> NYSE RQD COCKPIT → CIK 0001964738 ↗
Health Care • Medical/Dental Instruments
$81.33 ▼ -2.23 (-2.67%)
MKT CAP: $14.22B • VOL: 1.07M
SOLV // ROARABLE RATING & 5-PILLAR RQD CONFIDENCE 02:00 EST DETERMINISTIC ENGINE
PRIOR: RQD 45/100 [D] (+0 PT) • UNCHANGED
ROARABLE D
RQD CONFIDENCE
45 / 100 +0D
5 X 20-PT QUANT PILLARS
E 0 D 35 C 59 B 70 A 86+
Roarable Sell — Underperform / Distribution Warning
01 MASSIVE / SEC XBRL
Forensic Fundamentals
[LOCKED] FLAGGED
UNLOCK BELOW TO REVEAL
02 INSTITUTIONAL TAPE & TREND
Whale & Options Flow
9 / 20
WARNING
52W RANGE 67% • VS 200D +6.6% • RSI 43.4
03 SEC XBRL CAPITAL ALLOCATION
Insider & Capital Conviction
10 / 20
NEUTRAL
FCF YIELD -0.1% • P/E 8.5x • F-SCORE 6/9
04 FRED 90D r-MATRIX
Macro Regime Fit
9 / 20
WARNING
NEUTRAL • r(10Y)=-0.15 (+23bp) • r(OAS)=-0.30
05 10-K REDLINE AUDIT
Forensic 10-K Risk
[LOCKED] FLAGGED
UNLOCK BELOW TO REVEAL
ALERT

Why did SOLV's Forensic Fundamentals & Forensic 10-K Risk sub-score just flash a warning? Enter your email to unlock the full 5-Pillar Rating Breakdown + get instant alerts whenever SOLV is Upgraded or Downgraded.

SIG <GO> CROSS-FEED TRIANGULATION // PROPRIETARY ANOMALY ENGINE (1 ACTIVE ON SOLV)
ALL MARKET ANOMALIES <SIG>
▼ BEARISH // ACCRUAL & WORKING CAPITAL WATCHSIFTER 02 // ACCRUAL & RECEIVABLES FORENSICS
SEVERITY: 87/100 Z-SCORE: +3.98σ

SOLV Accounting Gap: Net Income (+220%) Outpaced OCF (-68.9%) With +19% Working-Capital Build

CASH CONVERSION GAP
+288.9% (NI vs OCF)
RECEIVABLES / WC BLOAT
+19.0% VS REV
60D C-SUITE FORM 4 SALES
0 OPEN-MKT DUMPS
[GEEK DESK FORENSIC NOTE // SEC XBRL × FORM 4 CROSS-CHECK]
SEC EDGAR XBRL CompanyFacts10-K/10-Q Working Capital ScheduleSEC Form 4 Executive Sales

SEC EDGAR XBRL triangulation on Solventum Corporation (SOLV) exposes a +288.9% Cash Conversion Gap as YoY Net Income growth (+220.0%) diverged from Operating Cash Flow growth (-68.9%). Non-cash current assets and receivables expanded +19.0% relative to top-line revenue growth. Monitor upcoming 10-Q cash realization closely for accrual mean-reversion.

SOLV // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +20.60%🛡️ HOLDING TREND SUPPORT
2026-11-02O $81.85H $83.56L $81.33C $81.33VOL 1.09M
RES: $102.0SUP: $80.74SMA50: $87.82SMA200: $78.40
$96.11$88.02$79.93$71.84$63.75RES $102.0SUP $80.74$81.332026-05-042026-06-172026-08-042026-09-182026-11-02
SOLV // INSTITUTIONAL BULL VS. BEAR FORENSIC DEBATE
NEUTRAL / PAIR TRADE CONVICTION: 52/100
BEAR 0
100 BULL

Solventum Corporation (SOLV) exhibits 53.5% gross margins and 18.7% return on invested capital within Health Care (Medical/Dental Instruments), balanced against a 7.3x enterprise multiple and 4.8% implied options volatility.

▲ INSTITUTIONAL BULL THESIS (LONG)
01. Operating Leverage & Capital Efficiency Moat

Sustained 53.5% gross profitability converts into 26.2% operating margin and 18.7% ROIC, outpacing sector cost of capital.

ROIC: 18.7% // GM: 53.5%
02. Top-Line Expansion & Cash Conversion

YoY revenue trajectory of +0.9% paired with -0.07% free cash flow yield supports self-funded R&D and capital return.

REV YOY: +0.9% // FCF YLD: -0.07%
03. Balance Sheet Solvency & Forensic Quality

Altman Z-Score of 2.25 and Piotroski F-Score of 6/9 indicate low near-term refinancing stress.

ALTMAN Z: 2.25 // F-SCORE: 6/9
▼ INSTITUTIONAL BEAR THESIS (SHORT / RISK)
01. Multiple Compression & Duration Sensitivity

Trading at 9.1x trailing P/E (8.5x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.

P/E: 9.1x // EV/EBITDA: 7.3x
02. Options Skew & Event Volatility Risk

Options market prices a ±5.2% implied move with a 0.85 put/call ratio around $81.33 max pain.

IMPL MOVE: ±5.2% // P/C: 0.85
03. Competitive Margin & CapEx Cycle Pressure

Elevated industry capital intensity and customer concentration in Medical/Dental Instruments require continuous execution to defend 18.7% net margins.

NET MARGIN: 18.7% // D/E: 1.00x
KEY CATALYST // Upcoming 10-Q/10-K XBRL margin progression, guidance revision vs 8.5x forward consensus, and institutional 13F positioning.
MACRO REGIME // Monitor US 10Y Real Yields (DFII10) and High-Yield Credit Spreads (OAS) for beta-adjusted multiple impact (Beta 1.06).
FORM 4 & 13F FLOW OPEN OWN <GO>
FILER SIDE $ VALUE
INSPECT FULL OWNERSHIP LEDGER IN OWN <GO>
UNUSUAL OPTIONS TAPE OPEN OPT <GO>
STRIKE / EXP TYPE PREMIUM
INSPECT GEX & CHAIN IN OPT <GO>
KEY VALUATION & PROFITABILITY RATIOS XBRL FA <GO>
TRAILING P/E 9.1x
FORWARD P/E 8.5x
EV / EBITDA 7.3x
FCF YIELD -0.07%
GROSS MARGIN 53.5%
OPERATING MARGIN 26.2%
NET MARGIN 18.7%
ROIC % 18.7%
REV GROWTH YOY +0.9%
DILUTED EPS TTM $9.14
DEBT / EQUITY 1.00x
DIVIDEND YIELD 0.00%
RSI-14 MOMENTUM 43.4
5Y EQUITY BETA 1.06
FRED MACRO SENSITIVITY (PEARSON r) ECST <GO>
MACRO CORRELATION CALIBRATION ACTIVE BELOW.
FRED MACRO REGIME STRESS-TEST SIMULATOR // SOLVPEARSON R VARIANCE ENGINE
01 // SELECT FEDERAL RESERVE & CREDIT SHOCK SCENARIO
02 // POSITION NOTIONAL EXPOSURE
HEADLINE STRESS SCORE
75/100SEVERE DRAWDOWN PRESSURE
PRIMARY FACTOR EXPOSURE
DFII10 // -0.61 r
Latest: 2.08%
EST. DIRECTIONAL MOVE
-8.50%
Implied Px: $74.42
EST. DOLLAR VARIANCE
-$4,248
On $50,000 Notional
[LOCKED // MULTI-FACTOR DRAWDOWN HEDGE & MACRO TRIGGER ALERT]

Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for SOLV & activate live FRED threshold breach alerts.

HEAD-TO-HEAD PEER COMPARISONS COMP <GO>